| Date Filed | Type | Description |
| 08/21/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 08/14/2023 |
8-K
| Quarterly results |
| 08/11/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/11/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/03/2023 |
8-K
| Other Events Interactive Data |
| 07/13/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 06/06/2023 |
8-K
| Other Events Interactive Data |
| 05/24/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/24/2023 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Other Events, Financial Statement... |
| 05/12/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/24/2023 |
CT ORDER
| Form CT ORDER - Confidential treatment order: |
| 04/14/2023 |
8-K
| Quarterly results |
| 03/31/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/31/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/09/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/31/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/31/2023 |
4
| Rubin Steven D (Director) has filed a Form 4 on Eloxx Pharmaceuticals, Inc.|
Txns:
| Granted 2,859 options to buy
@ $4, valued at
$11.4k
|
|
| 01/31/2023 |
4
| Kariv Tomer (Director) has filed a Form 4 on Eloxx Pharmaceuticals, Inc.|
Txns:
| Granted 2,859 options to buy
@ $4, valued at
$11.4k
|
|
| 01/31/2023 |
4
| Androski Lindsay (Director) has filed a Form 4 on Eloxx Pharmaceuticals, Inc.|
Txns:
| Granted 2,859 options to buy
@ $4, valued at
$11.4k
|
|
| 01/27/2023 |
4
| Aggarwal Sumit (PRESIDENT AND CEO) has filed a Form 4 on Eloxx Pharmaceuticals, Inc.|
Txns:
| Granted 68,700 options to buy
@ $4.27, valued at
$293.3k
|
|
| 01/27/2023 |
4
| MODUR VIJAY (HEAD OF R&D) has filed a Form 4 on Eloxx Pharmaceuticals, Inc.|
Txns:
| Granted 30,000 options to buy
@ $4.27, valued at
$128.1k
|
|
| 12/01/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
8-K
| Quarterly results |
| 11/10/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 10/31/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 10/17/2022 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 10/14/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 09/15/2022 |
8-K
| Investor presentation |
| 08/15/2022 |
8-K
| Quarterly results |
| 08/12/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 07/15/2022 |
8-K
| Quarterly results |
| 07/06/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/06/2022 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
|